^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Insulin receptor antagonist

    Related drugs:
    14d
    sunRIZE: RZ358 Treatment for Congenital Hyperinsulinism (clinicaltrials.gov)
    P3, N=56, Active, not recruiting, Rezolute | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Nov 2027 | Trial primary completion date: Apr 2025 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    2ms
    Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor (clinicaltrials.gov)
    P=N/A, N=0, Available, Rezolute
    New trial
    3ms
    A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (clinicaltrials.gov)
    P3, N=16, Recruiting, Rezolute | N=48 --> 16
    Enrollment change
    7ms
    Mining of Targeted Therapeutic Drugs for Hepatocellular Carcinoma based on Programmed Death-related Features and Construction of an Imaging Histology Diagnostic Model. (PubMed, Curr Top Med Chem)
    This study identified key genes associated with PCD in LIHC, revealed its immunoregulatory mechanism, and predicted potential target drugs, providing new ideas for precision treatment and diagnosis of hepatocellular carcinoma.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD200R1 (CD200 Receptor 1)
    |
    GSK 1838705A
    9ms
    A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism (clinicaltrials.gov)
    P3, N=48, Recruiting, Rezolute | Not yet recruiting --> Recruiting
    Enrollment open
    10ms
    tHI: A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism (clinicaltrials.gov)
    P3, N=48, Not yet recruiting, Rezolute
    New P3 trial
    almost2years
    sunRIZE: RZ358 Treatment for Congenital Hyperinsulinism (clinicaltrials.gov)
    P3, N=56, Recruiting, Rezolute | Not yet recruiting --> Recruiting
    Enrollment open
    2years
    sunRIZE: RZ358 Treatment for Congenital Hyperinsulinism (clinicaltrials.gov)
    P3, N=56, Not yet recruiting, Rezolute
    New P3 trial
    over2years
    Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-insulin Receptor Antibody (ENDO 2023)
    High-dose diazoxide, everolimus, dexamethasone, glucagon, pasireotide, or enteral feeding did not produce a response. No adverse effects have been observed. In summary, the anti-insulin receptor monoclonal antibody RZ358 effectively controlled hypoglycemia refractory to multiple other therapies, allowing restoration of normoglycemia and enabling additional successful cancer therapy.
    Late-breaking abstract
    |
    IR (Insulin receptor) • MEN1 (Menin 1)
    |
    everolimus • dexamethasone • Signifor (pasireotide)
    almost3years
    Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability. (PubMed, J Neurooncol)
    Meningioma cell growth is critically dependent on autocrine miR-483/IGF-2 stimulation and the IGF-2 pathway provides a feasible meningioma treatment target.
    Journal • Tumor cell
    |
    IGF2 (Insulin-like growth factor 2) • MIR483 (MicroRNA 483)
    |
    Zykadia (ceritinib) • GSK 1838705A
    over4years
    IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R. (PubMed, Cell Death Dis)
    In addition, the combined treatment of ACLY inhibitor ETC-1002 and IGF1R inhibitor Linsitinib dramatically suppressed HOXA13-mediated CRC metastasis. In conclusion, HOXA13 is a prognostic biomarker in CRC patients. Targeting the IGF1-HOXA13-IGF1R positive feedback loop may provide a potential therapeutic strategy for the treatment of HOXA13-driven CRC metastasis.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • IGF1 (Insulin-like growth factor 1)
    |
    HIF1A expression
    |
    linsitinib (ASP7487)